Photo: https://depositphotos.com
Jul 30, 2025, 18:22
AIM-HI Portfolio Company Yiviva Reports Promising Phase 2b Results for YIV-906
AIM-HI Accelerator Fund shared a post on LinkedIn:
“AIM-HI portfolio company Yiviva reports promising Phase 2b results!
At ASCO25 and ESMOGI25, Yiviva presented new data showing that YIV-906, when combined with sorafenib, significantly improves survival and tolerability for patients with advanced hepatocellular carcinoma and chronic hepatitis B.
Key findings:
- Median overall survival nearly doubled
- Improved tumor progression timelines
- Better treatment tolerance
Backed by AIM-HI, NFCR, AFCR, and Yale, Yiviva is redefining cancer treatment by merging systems biology with centuries-old medicinal knowledge.
More posts featuring AIM-HI Accelerator Fund.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 30, 2025, 18:22
Jul 30, 2025, 18:22
Jul 30, 2025, 17:38
Jul 30, 2025, 17:34
Jul 30, 2025, 17:31
Jul 30, 2025, 17:25
Jul 30, 2025, 17:24
Jul 30, 2025, 17:17